Elanco Animal Health (NYSE:ELAN) announces quarterly earnings results

VaselineAugust 11, 2024

0 2 minutes read

Elanco Animal Health (NYSE:ELAN – Get Free Report ) released its quarterly earnings data on Thursday. The company reported $0.30 EPS for the quarter, topping the consensus estimate of $0.24 by $0.06, Briefing.com reports. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.15 billion. During the same period in the previous year, the firm earned $0.18 EPS. The company’s revenue for the quarter was up 12.0% year-over-year.

Elanco Animal Health stock rose 0.4%

ELAN opened at $13.04 on Friday. The company has a fifty day moving average of $15.02 and a two hundred day moving average of $15.38. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.96, and a current ratio of 3.29. Elanco Animal Health has a fifty-two week low of $8.52 and a fifty-two week high of $18.80. The stock has a market cap of $6.44 billion, a price-to-earnings ratio of -4.92, a PEG ratio of 1.27 and a beta of 1.42.

Analyst upgrades and downgrades

Several equities research analysts have commented on ELAN shares. Barclays reduced their target price on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. Piper Sandler cut their price target on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Monday, July 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average target price of $17.57.

Want more great investment ideas?

Get the latest Elanco Animal Health Report

Insider trading at Elanco Animal Health

In other Elanco Animal Health news, Director William F. Doyle acquired 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The shares were acquired at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the acquisition, the director now directly owns 76,330 shares in the company, valued at $1,296,083.40. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed via this hyperlink. Corporate insiders own 0.57% of the company’s shares.

About Elanco Animal Health

(Get a free report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. Offers disease prevention products for pet health, such as parasiticides and vaccine products that protect pets from worms, fleas and ticks under the Seresto, Advantage, Advantix and Advocate brands; pet health medications for pain, osteoarthritis, ear infections, cardiovascular and dermatological indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides and other products for use in poultry and aquaculture production, as well as health nutritional products, including enzymes, probiotics and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides and other products used in ruminant and swine production under the brands Rumensin and Baytril.